Physician profile
John B Malcolm
NPI 1558582692
$4,079.40
in general payments reported to CMS, 2019-2025
31 companies · $591 in 2025
The $591 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,965 · 2020: $298 · 2021: $123 · 2022: $33.59 · 2023: $312 · 2024: $756 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,534 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,534.24 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $822.85 | 2019-2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $809.68 | 2019-2025 | |
| Boston Scientific Corporation | $620.18 | 2019-2020 | |
| Astellas Pharma US INC | $234.46 | 2019-2023 | Xtandi |
| Tempus Ai, INC | $222.83 | 2024 | |
| Dendreon Pharmaceuticals LLC | $175.71 | 2019-2020 | |
| Pfizer INC. | $143.75 | 2019-2024 | |
| Abbvie INC. | $125.00 | 2024 | |
| Ethicon US, LLC | $123.96 | 2019 | |
| Coloplast Corp | $95.70 | 2019-2020 | |
| Travere Therapeutics, INC. | $70.78 | 2019-2020 | |
| Sn Holdings, LLC | $69.00 | 2021 | |
| Ferring Pharmaceuticals INC. | $67.78 | 2020-2025 | Adstiladrin |
| Blue Earth Diagnostics | $64.09 | 2023-2024 | |
| Urogen Pharma, INC. | $55.17 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $49.90 | 2019 | |
| Sumitomo Pharma America, INC. | $42.26 | 2023-2025 | Orgovyx |
| Neotract INC. | $41.83 | 2019 | |
| Novartis Pharmaceuticals Corporation | $31.54 | 2024-2025 | |
| Endo Pharmaceuticals INC. | $29.45 | 2019-2023 | Aveed, Xiaflex, Edex |
| Sun Pharmaceutical Industries INC. | $23.04 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $22.72 | 2025 | |
| Amgen INC. | $20.51 | 2019 | |
| Teleflex LLC | $19.52 | 2019 | |
| Medtronic USA, INC. | $18.90 | 2019 | |
| Allergan, INC. | $18.90 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $16.66 | 2019 | |
| Dentsply Ih INC. | $15.48 | 2019 | |
| Olympus America INC. | $15.45 | 2020 | |
| Zyla Life Sciences, INC. | $12.30 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$637,739.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Malcolm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.